The presence of circulating donor-specific antihuman leukocyte antigen (HLA) antibodies (DSAs) is considered as a mandatory criterion for AMR after HTx. DSA are known prognostic biomarkers of outcome, for example, recipients with de-novo DSA have a …

May 1, 2021 · Donor specific antibody (DSA) after heart transplant (HTx) is detected in approximately 25% of HTx recipients. DSA that is accompanied by symptoms of heart failure, left ventricular dysfunction by echocardiography or wall …

Oct 1, 2018 · Donor-specific antibodies (DSA) are integral to the development of antibody-mediated rejection (AMR). Chronic AMR is associated with high mortality and an increased risk for cardiac allograft vasculopathy (CAV).

De novo donor-specific antibodies (dnDSAs) have been associated with cardiac allograft vasculopathy, antibody-mediated rejection, and mortality. Advances in detection methods and international guideline recommendations have encouraged the adoption of screening protocols among heart transplant units.

Because DSA, particularly de novo antibodies, are associated with poor outcomes after heart transplant, it is important to understand differences in the development and detection of pre-existing versus de novo antibodies (13–16). There are two mechanisms that result in “new” expression of antibodies after transplant.

Jul 1, 2010 · Preformed donor HLA-specific antibodies are a known indicator for poor patient survival after cardiac transplantation. The role of de novo donor-specific antibodies (DSA) formed after cardiac transplantation is less clear.

Jan 11, 2023 · Newly detected donor HLA-specific antibodies (DSA) are historically known to be associated with reduced survival in heart transplant patients. Our objective is to clarify the modern incidence of DSA and determine its relationship with survival and MACE.

Recent findings: De novo DSA after heart transplantation is common and associated with rejection, cardiac allograft vasculopathy, allograft failure, and mortality. Advances in methods for HLA antibody detection have enabled identification of DSA with high precision and sensitivity.

Donor Specific Antibodies (“DSA”) DSAs are antibodies that you may develop specifically against your new heart. DSA testing allows physicians to monitor the development of these antibodies over time.

Antibody‐mediated graft rejection caused by donor‐specific antibodies (DSA‐MR) remains a serious problem after heart transplantation (HTx). IgM‐enriched human intravenous immunoglobulin (IGM‐IVIG) consists of 76% IgG, 12% IgM, and 12% IgA and provides a new multifactorial approach for DSA‐MR.